95 related articles for article (PubMed ID: 5153084)
1. Clinical evaluation of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in malignant melanoma and other neoplasms: comparison of twice-weekly and daily administration schedules.
Gottlieb JA; Serpick AA
Oncology; 1971; 25(3):225-33. PubMed ID: 5153084
[No Abstract] [Full Text] [Related]
2. Study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with disseminated melanoma.
Gerner RE; Moore GE
Cancer Chemother Rep; 1973 Feb; 57(1):83-4. PubMed ID: 4704107
[No Abstract] [Full Text] [Related]
3. Clinical trials of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) given intravenously in the treatment of malignant melanoma in Uganda.
Vogel CL; Comis R; Ziegler JL; Kiryabwire JW
Cancer Chemother Rep; 1971 Apr; 55(2):143-9. PubMed ID: 5118684
[No Abstract] [Full Text] [Related]
4. Chemotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and dactinomycin.
Gerner RE; Moore GE; Didolkar MS
Cancer; 1973 Oct; 32(4):756-60. PubMed ID: 4751912
[No Abstract] [Full Text] [Related]
5. Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Cancer Res; 1969 Nov; 29(11):1944-51. PubMed ID: 5358212
[No Abstract] [Full Text] [Related]
6. Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.
Einhorn LH; McBride CM; Luce JK; Caoili E; Gottlieb JA
Cancer; 1973 Oct; 32(4):749-55. PubMed ID: 4751911
[No Abstract] [Full Text] [Related]
7. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
Luce JK; Thurman WG; Isaacs BL; Talley RW
Cancer Chemother Rep; 1970 Apr; 54(2):119-24. PubMed ID: 4334086
[No Abstract] [Full Text] [Related]
8. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
Gutterman JU; Mavligit G; Gottlieb JA; Burgess MA; McBride CE; Einhorn L; Freireich EJ; Hersh EM
N Engl J Med; 1974 Sep; 291(12):592-7. PubMed ID: 4851001
[No Abstract] [Full Text] [Related]
9. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of malignant tumors other than melanoma.
Kingra GS; Comis R; Olson KB; Horton J
Cancer Chemother Rep; 1971 Jun; 55(3):281-3. PubMed ID: 5115849
[No Abstract] [Full Text] [Related]
10. Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
Cowan DH; Bergsagel DE
Cancer Chemother Rep; 1971 Apr; 55(2):175-81. PubMed ID: 5118686
[No Abstract] [Full Text] [Related]
11. Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) on immunity in patients with malignant melanoma.
Bruckner HW; Mokyr MB; Mitchell MS
Cancer Res; 1974 Jan; 34(1):181-3. PubMed ID: 4588545
[No Abstract] [Full Text] [Related]
12. Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.
Falkson G; Van der Merwe AM; Falkson HC
Cancer Chemother Rep; 1972 Oct; 56(5):671-7. PubMed ID: 4569061
[No Abstract] [Full Text] [Related]
13. Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer.
Stolinsky DC; Bogdon DL; Solomon J; Bateman JR
Cancer; 1972 Sep; 30(3):654-9. PubMed ID: 5075351
[No Abstract] [Full Text] [Related]
14. 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.
Carter SK; Friedman MA
Eur J Cancer (1965); 1972 Feb; 8(1):85-92. PubMed ID: 4552317
[No Abstract] [Full Text] [Related]
15. Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
Gams RA; Carpenter JT
Cancer Chemother Rep; 1974; 58(5 Pt 1):753-4. PubMed ID: 4214608
[No Abstract] [Full Text] [Related]
16. Elevated inary excretion of 4-aminoimidazole-5-carboxamide in patients after intravenous injection of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide.
Housholder GE; Loo TL
Life Sci; 1969 May; 8(9):533-6. PubMed ID: 5791705
[No Abstract] [Full Text] [Related]
17. 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of advanced acute lymphocytic leukemia in children.
Finklestein JZ; Albo V; Ertel I; Karon M; Hammond D
Cancer Chemother Rep; 1972 Aug; 56(4):523-6. PubMed ID: 4507686
[No Abstract] [Full Text] [Related]
18. Intra-arterial therapy of melanoma with dimethyl triazeno imidazole carboxamide (NSC-45388).
Savlov ED; Hall TC; Oberfield RA
Cancer; 1971 Nov; 28(5):1161-4. PubMed ID: 5166498
[No Abstract] [Full Text] [Related]
19. Combination chemotherapy with CCNU (NSC-79037) and 5-(3, 3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196).
Chang H; Freireich EJ; Khaliq A; Einhorn L; Gottlieb JA
Cancer Chemother Rep; 1975; 59(4):769-71. PubMed ID: 1100230
[No Abstract] [Full Text] [Related]
20. Response of localized melanoma to intra-arterial dimethyl triazeno imidazole carboxamide: a case report.
Savlov ED; Hall TC
J Surg Oncol; 1970; 2(4):341-7. PubMed ID: 5520849
[No Abstract] [Full Text] [Related]
[Next] [New Search]
